Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.

Detalles Bibliográficos

Principais autores:	Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad, Maria Lajer, Christina Shay, Lisette Koeneman, Soulmaz Fazeli Farsani, Leo Niskanen, Sigrun Halvorsen
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2024-01-01
Series:	Journal of Diabetes Research
Acceso en liña:	http://dx.doi.org/10.1155/2024/6142211
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!